In this work,a high-strength Mg–10Gd–6Y–1.5Zn–0.5Zr(wt.%)alloy was fabricated by successive multi-pass equal channel angular pressing(ECAP).The microstructure and mechanical property of as-cast and ECAP alloys wer...In this work,a high-strength Mg–10Gd–6Y–1.5Zn–0.5Zr(wt.%)alloy was fabricated by successive multi-pass equal channel angular pressing(ECAP).The microstructure and mechanical property of as-cast and ECAP alloys were systematically researched by X-ray diffractometer,scanning electron microscopy,transmission electron microscopy and compression test.The results show that the microstructure of as-cast alloy consists ofα-Mg grains,Mg24Y5 networks,18R blocks,fine 14H lamellas,and fewY-rich particles.After 8 passes ECAP,dynamic recrystallization ofα-Mg is developed and their average grain size decreases to about 1μm.The network Mg_(24)Y_(5) phase at grain boundaries is broken into small particles with average diameter lower than 0.5μm.Moreover,18R blocks are kinked and delaminated,or broken into small particles and blended with Mg24Y5 particles.14H lamellas grow gradually or are dynamically precipitated within certainα-Mg grains.Compression tests indicate that 8p ECAP alloy exhibits excellent mechanical property with compressive strength of 537 MPa and fracture strain of 17.0%.The significant improvement for both strength and ductility of deformed alloy could be ascribed to DRX grains,refined Mg24Y5 particles,18R kinking and dynamical precipitation of 14H.展开更多
Objectives: The aim of this study was to assess the levels of Y-box binding protein 1 (YBX-1) and interleukin 6 (IL-6) in the sera of metastatic and non-metastatic breast cancer patients (BC), investigate their clinic...Objectives: The aim of this study was to assess the levels of Y-box binding protein 1 (YBX-1) and interleukin 6 (IL-6) in the sera of metastatic and non-metastatic breast cancer patients (BC), investigate their clinicopathological significance and to analyze their potential use as biomarkers of breast cancer metastasis. Methods: The study included ninety subjects sub-grouped equally into metastatic BC, non-metastatic BC and healthy volunteers. Serum YBX-1 and IL-6 were quantified using ELISA technique while CA 15-3 was quantified using IRMA kit. Clinical data were collected from patients’ records. Results: YBX-1 (p < 0.001), IL-6 (p < 0.001) and CA15-3 (p = 0.017, 0.001) were significantly elevated in metastatic and non-metastatic BC patients compared to healthy controls, however, only YBX-1 (p 0.001) showed a significant difference with cancer metastasis. Generally, YBX-1 and IL-6 were correlated with worse histological grade and late clinical stage in breast cancer patients and they were also associated with axillary lymph nodes involvement and positive vascular invasion in metastatic BC patients. Serum YBX-1 and IL-6 levels were positively correlated to each other (rs = 0.615, p < 0.001) and they showed high sensitivity and specificity compared to CA 15-3 (p < 0.001 and p = 0.004 for YBX-1 and IL-6 respectively) for predicting cancer metastasis. Conclusions: Serum YBX-1 and IL-6 are potential biomarkers of breast cancer patients with significant correlation with bad clinicopathological characteristics. Serum YBX-1 and IL-6 have superior sensitivity and specificity compared to CA15-3 and can serve as potential follow up and prognostic markers.展开更多
基金Project(cstc2015jcyj BX0036)supported by Chongqing Research Program of Basic Research and Frontier Technology,ChinaProject(51571040)supported by the National Natural Science Foundation of ChinaProject supported by the Sharing Fund of Chongqing University’s Large-scale Equipment,China
基金Project (50271054) supported by the National Natural Science Foundation of ChinaProject (20070700003) supported by the Doctorate Programs Foundation of Ministry of Education of China+1 种基金Project (102102210031) supported by the Science and Technologies Foundation of Henan Province,ChinaProject (2010A430008) supported by the Natural Science Foundation of Henan Educational Committee of China
基金the Natural Science Foundation of Jiangsu Province of China(No.BK20160869)the financial support from the Nantong Science and Technology Project(No.GY12015009)+1 种基金the Fundamental Research Funds for the Central Universities(No.2015B01314)the National Natural Science Foundation of China(No.51501039).
文摘In this work,a high-strength Mg–10Gd–6Y–1.5Zn–0.5Zr(wt.%)alloy was fabricated by successive multi-pass equal channel angular pressing(ECAP).The microstructure and mechanical property of as-cast and ECAP alloys were systematically researched by X-ray diffractometer,scanning electron microscopy,transmission electron microscopy and compression test.The results show that the microstructure of as-cast alloy consists ofα-Mg grains,Mg24Y5 networks,18R blocks,fine 14H lamellas,and fewY-rich particles.After 8 passes ECAP,dynamic recrystallization ofα-Mg is developed and their average grain size decreases to about 1μm.The network Mg_(24)Y_(5) phase at grain boundaries is broken into small particles with average diameter lower than 0.5μm.Moreover,18R blocks are kinked and delaminated,or broken into small particles and blended with Mg24Y5 particles.14H lamellas grow gradually or are dynamically precipitated within certainα-Mg grains.Compression tests indicate that 8p ECAP alloy exhibits excellent mechanical property with compressive strength of 537 MPa and fracture strain of 17.0%.The significant improvement for both strength and ductility of deformed alloy could be ascribed to DRX grains,refined Mg24Y5 particles,18R kinking and dynamical precipitation of 14H.
文摘Objectives: The aim of this study was to assess the levels of Y-box binding protein 1 (YBX-1) and interleukin 6 (IL-6) in the sera of metastatic and non-metastatic breast cancer patients (BC), investigate their clinicopathological significance and to analyze their potential use as biomarkers of breast cancer metastasis. Methods: The study included ninety subjects sub-grouped equally into metastatic BC, non-metastatic BC and healthy volunteers. Serum YBX-1 and IL-6 were quantified using ELISA technique while CA 15-3 was quantified using IRMA kit. Clinical data were collected from patients’ records. Results: YBX-1 (p < 0.001), IL-6 (p < 0.001) and CA15-3 (p = 0.017, 0.001) were significantly elevated in metastatic and non-metastatic BC patients compared to healthy controls, however, only YBX-1 (p 0.001) showed a significant difference with cancer metastasis. Generally, YBX-1 and IL-6 were correlated with worse histological grade and late clinical stage in breast cancer patients and they were also associated with axillary lymph nodes involvement and positive vascular invasion in metastatic BC patients. Serum YBX-1 and IL-6 levels were positively correlated to each other (rs = 0.615, p < 0.001) and they showed high sensitivity and specificity compared to CA 15-3 (p < 0.001 and p = 0.004 for YBX-1 and IL-6 respectively) for predicting cancer metastasis. Conclusions: Serum YBX-1 and IL-6 are potential biomarkers of breast cancer patients with significant correlation with bad clinicopathological characteristics. Serum YBX-1 and IL-6 have superior sensitivity and specificity compared to CA15-3 and can serve as potential follow up and prognostic markers.
